Synergistic Activity of Deguelin and Fludarabine in Cells from Chronic Lymphocytic Leukemia Patients and in the New Zealand Black Murine Model-Reference-Cited by-同舟云学术

Synergistic Activity of Deguelin and Fludarabine in Cells from Chronic Lymphocytic Leukemia Patients and in the New Zealand Black Murine Model

Published:2016-04-21 Issue:4 Volume:11 Page:e0154159
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Rebolleda Nerea,Losada-Fernandez Ignacio,Perez-Chacon Gema,Castejon Raquel,Rosado Silvia,Morado Marta,Vallejo-Cremades Maria Teresa,Martinez Andrea,Vargas-Nuñez Juan A.,Perez-Aciego Paloma^ORCID

Funder

Fondo de Investigaciones Sanitarias, Ministerio de Sanidad

Fundación LAIR

Caja de Navarra

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference69 articles.

1. Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia;KR Rai;N Engl J Med,2000

2. Chronic lymphocytic leukemia;M Hallek;Ann Oncol Off J Eur Soc Med Oncol ESMO,2010

3. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment;M Hallek;Am J Hematol,2015

4. Treatment of fludarabine-refractory chronic lymphocytic leukemia;AM Tsimberidou;Cancer,2009

5. Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications;Y Herishanu;Hematol Oncol Clin North Am,2013

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The PI3K signaling pathway; from normal lymphopoiesis to lymphoid malignancies;Expert Review of Anticancer Therapy;2024-05-08

2. Pharmacological basis and new insights of deguelin concerning its anticancer effects;Pharmacological Research;2021-12

3. Deguelin targets multiple oncogenic signaling pathways to combat human malignancies;Pharmacological Research;2021-04

4. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib‐resistantBRAFV600Emutation bearing metastatic melanoma cells;Molecular Carcinogenesis;2019-06-18

5. Biopharmacological considerations for accelerating drug development of deguelin, a rotenoid with potent chemotherapeutic and chemopreventive potential;Cancer;2019-04